NASDAQ : ERNA
Ernexa Therapeutics Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 1.97 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 3.22M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 3.22M |
| Enterprise Value | -1.46M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 13, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 1.63M |
| Shares Outstanding | 1.63M |
| Shares Change (YoY) | +467.90% |
| Shares Change (QoQ) | +49.37% |
| Owned by Insiders (%) | 25.40% |
| Owned by Institutions (%) | 6.22% |
| Float | 1.22M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.72 |
| P/TBV Ratio | 1.01 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 2.01 |
| Quick Ratio | 1.74 |
| Debt / Equity | 0.11 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -434.74 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -320.72% |
| Return on Assets (ROA) | -105.57% |
| Return on Invested Capital (ROIC) | -170.89% |
| Return on Capital Employed (ROCE) | -346.97% |
| Weighted Average Cost of Capital (WACC) | 17.56% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.75M |
| Employee Count | 7 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | -96,000 |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 2.65 |
| 52-Week Price Change | -95.52% |
| 50-Day Moving Average | 3.31 |
| 200-Day Moving Average | 7.35 |
| Relative Strength Index (RSI) | 32.48 |
| Average Volume (20 Days) | 63,838 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 19,877 |
| Short Previous Month | 19,725 |
| Short % of Shares Out | 1.22% |
| Short % of Float | 1.63% |
| Short Ratio (days to cover) | 0.23 |
Incomestatement
| Measure | Value |
|---|
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -11.74M |
| Pretax Income | -12.35M |
| Net Income | -12.27M |
| EBITDA | -11.69M |
| EBIT | -11.74M |
| Earnings Per Share (EPS) | -$18.60 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 5.03M |
| Total Debt | 349,000 |
| Net Cash | 4.68M |
| Net Cash Per Share | $2.87 |
| Equity (Book Value) | 3.20M |
| Book Value Per Share | 2.73 |
| Working Capital | 2.96M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -8.84M |
| Capital Expenditures | -42,000 |
| Depreciation & Amortization | 47,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -8.88M |
| FCF Per Share | -$5.44 |
Margins
| Measure | Value |
|---|
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -467.90% |
| Shareholder Yield | -467.90% |
| Earnings Yield | -944.32% |
| FCF Yield | -276.07% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | May 4, 2026 |
| Split Type | Reverse |
| Split Ratio | 1:25 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |